2020
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer
Bar N, Costa F, Das R, Duffy A, Samur M, McCachren S, Gettinger S, Neparidze N, Parker TL, Bailur JK, Pendleton K, Bajpai R, Zhang L, Xu ML, Anderson T, Giuliani N, Nooka A, Cho HJ, Raval A, Shanmugam M, Dhodapkar KM, Dhodapkar M. Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. JCI Insight 2020, 5 PMID: 32427579, PMCID: PMC7406262, DOI: 10.1172/jci.insight.129353.Peer-Reviewed Original ResearchConceptsPD-L1 blockadePD-1 blockadeAsymptomatic multiple myelomaMonocyte-derived DCsPD-L1Immunologic effectsT cellsMyeloid cellsAntigen-specific T cell expansionAnti-PD-1 therapyMyeloid antigen-presenting cellsDistinct inflammatory signatureSystemic immunologic effectsLung cancer patientsT cell expansionAntigen-presenting cellsMyeloid activationMyeloid inflammationInflammatory signatureNIH/NCICheckpoint blockadeDC maturationL1 therapyCombination therapyInflammatory phenotype
2016
Induction of anti-tumor CD8 T cell responses by experimental ECP-induced human dendritic antigen presenting cells
Kibbi N, Sobolev O, Girardi M, Edelson RL. Induction of anti-tumor CD8 T cell responses by experimental ECP-induced human dendritic antigen presenting cells. Transfusion And Apheresis Science 2016, 55: 146-152. PMID: 27317354, DOI: 10.1016/j.transci.2016.06.001.Peer-Reviewed Original ResearchConceptsCD8 T cell responsesCutaneous T-cell lymphomaT cell responsesCell responsesCD8 T cell populationsMonocyte-derived DCsAnti-tumor immunityT cell populationsT-cell lymphomaAntigen presenting cellsClass I major histocompatibilityCentral mechanistic roleMelanoma-associated proteinImmunotherapeutic managementHost diseaseAllograft rejectionPresenting cellsDendritic antigenImmunologic reactionsCell lymphomaMalignant cloneMajor histocompatibilityPathogenic clonesCell populationsAntigen
2013
Age-dependent dysregulation of innate immunity
Shaw AC, Goldstein DR, Montgomery RR. Age-dependent dysregulation of innate immunity. Nature Reviews Immunology 2013, 13: 875-887. PMID: 24157572, PMCID: PMC4096436, DOI: 10.1038/nri3547.Peer-Reviewed Original ResearchConceptsMetabolic syndromeIntracellular killingInnate immunityToll-like receptor functionNeutrophil extracellular trap formationBasal cytokine productionInnate immune dysregulationDendritic cell populationsMonocyte-derived DCsChronic viral infectionsMyeloid cells-1Pro-inflammatory milieuChronic inflammatory conditionsInnate immune activationVirus-infected macrophagesExtracellular trap formationAge-dependent dysregulationInnate immune systemPattern recognition receptorsAge-associated alterationsMacrophage colony-stimulating factorGranulocyte/macrophage colony-stimulating factorColony-stimulating factorTLR expressionImmune dysregulation
2006
In vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients
Tobiásová Z, Pospíšilová D, Miller A, Minárik I, Sochorová K, Špíšek R, Rob L, Bartůňková J. In vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients. Clinical Immunology 2006, 122: 18-27. PMID: 17059893, DOI: 10.1016/j.clim.2006.09.003.Peer-Reviewed Original ResearchConceptsOvarian cancer patientsCancer patientsDendritic cellsAutologous irradiated tumor cellsLymphocyte IFN-gamma productionTumor cellsAntigen-pulsed DCsIFN-gamma ELISPOTMonocyte-derived DCsMaturation of DCsIrradiated tumor cellsIFN-gamma productionNew treatment optionsAbility of DCsResidual tumour diseaseProliferation of lymphocytesApoptotic tumor cellsTumor cell apoptosisDC vaccinesAutologous lymphocytesLymphocyte responsesStandard treatmentTreatment optionsOvarian cancerPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply